Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Date
2024-05-28ICR Author
Author
Zinzani, PL
Salles, G
Moskowitz, AJ
Santoro, A
Mehta, A
Barr, PM
Mehta-Shah, N
Collins, GP
Ansell, SM
Brody, JD
Domingo-Domenech, E
Johnson, NA
Cunningham, D
Ferrari, S
Lisano, J
Krajewski, J
Wen, R
Akyol, A
Crowe, R
Savage, KJ
Type
Journal Article
Metadata
Show full item recordDOI
Collections
Subject
Humans
Brentuximab Vedotin
Lymphoma, T-Cell, Peripheral
Nivolumab
Lymphoma, T-Cell, Cutaneous
Male
Middle Aged
Female
Antineoplastic Combined Chemotherapy Protocols
Aged
Neoplasm Recurrence, Local
Adult
Skin Neoplasms
Research team
Medicine (RMH)
Language
eng
Date accepted
2024-02-28
License start date
2024-05-28
Citation
Blood Advances, 2024, 8 (10), pp. 2400 - 2404
Publisher
ELSEVIER